Chemical and Structural Strategies to Selectively Target mTOR Kinase.

Authors:
Borsari C; De Pascale M; Wymann MP.

Journal:
ChemMedChem

Publication Year: 2021

DOI:
10.1002/cmdc.202100332

PMCID:
PMC8518124

PMID:
34114360

View on PubMed View on PMC View Publisher
Journal Information

Full Title: ChemMedChem

Abbreviation: ChemMedChem

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Exploring Covalent Bond Formation at Tyr-82 for Inhibition of Ral GTPase Activation.
Landgraf AD; Yeh IJ; Ghozayel MK and 3 more (2023) - Transparency Score: 3/6
2-Amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles with Microtubule-Disruptive, …
Köhler LHF; Reich S; Begemann G and 2 more (2022) - Transparency Score: 3/6
7H-Pyrrolo[2,3-d]pyrimidine-4-amines as Potential Inhibitors of Plasmodium falciparum Calcium-Depen…
Seanego TD; Chavalala HE; Henning HH and 4 more (2022) - Transparency Score: 4/6
8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonucleas…
Jung E; Majima R; Edwards TC and 3 more (2022) - Transparency Score: 3/6
Advanced Pyrrolidine-Carbamate Self-Immolative Spacer with Tertiary Amine Handle Induces Superfast …
Dal Corso A; Frigoli M; Prevosti M and 5 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors declare no conflict of interest."

Evidence found in paper:

"The authors thank the EFMC and ChemMedChem editors and board members for the invitation to contribute to the EFMC‐ChemMedChem 2021 Early Career Special Collection – EuroMedChemTalents to CB. This work was supported by the Innosuisse grant 37213.1 IP‐LS, EU Horizon 2020, ITN 675392‐Ph.D; the Novartis Foundation for medical‐biological Research grant 14B095; the Swiss Commission for Technology and Innovation (CTI) by PFLS‐LS grant 17241.1; the Stiftung für Krebsbekämpfung grant 341, the Swiss National Science Foundation grant 310030_189065 to MPW. Open access funding provided by CSAL."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025